Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31299440 | 1.00 | USP2 (0.61) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL16903431 | 1.00 | USP2 (0.61) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL31328554 | 0.90 | USP2 (0.56) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL18065511 | 0.87 | USP2 (0.64) | USP2SMN1; SMN2RECQLGPR119PIK3R1 | |
| SCHEMBL24692803 | 0.84 | SMN1; SMN2 (0.59) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL31041013 | 0.84 | USP2 (0.59) | USP2SMN1; SMN2RECQLHPGDEPHX2 | |
| SCHEMBL25866966 | 0.83 | USP2 (0.63) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL30987056 | 0.82 | USP2 (0.58) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL23707226 | 0.82 | USP2 (0.58) | USP2SMN1; SMN2RECQLGPR119HPGD | |
| SCHEMBL14801055 | 0.82 | USP2 (0.50) | USP2SMN1; SMN2RECQLHPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624033-B2 | KRAS inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4735439-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735440-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250250271-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250154148-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-15 | — | — | US | disclosed |
| WO-2025006962-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025006967-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154148-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | USP2 640/4885SMN1; SMN2 3520/4885RECQL 486/4885 |
| US-20250250271-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | USP2 640/4885SMN1; SMN2 3520/4885RECQL 486/4885 |
| US-12624033-B2 | KRAS inhibitors | KRAS, NRAS, BRAF | USP2 2756/4885SMN1; SMN2 2996/4885RECQL 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.